Roth Capital Markets analyst Chip Moore reaffirmed his “Buy” rating and $15.00 price target on Tecogen (Tecogen Stock Quote, Chart, News, Analysts, Financials NYSE:TGEN), saying the company is gaining meaningful traction in the emerging data-centre cooling market. In a November 13 note following Q3 results, Moore said Tecogen’s long-standing expertise in cogeneration positions it to […]
Roth Capital Markets analyst Jonathan Aschoff maintained his “Buy” rating and US$30.00 price target on Tenax Therapeutics (Tenax Therapeutics Stock Quote, Chart, News, Analysts, Financials NASDAQ:TENX), saying the company remains well-funded through late-stage development of its cardiopulmonary drug candidate TNX-103 and is positioned for a major Phase 3 data cycle in 2026. In a Nov. […]
Share
Tweet
Share
